Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.0 (2)
  • Medicine

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. 1 day ago ·  Video

    Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

    Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.   Key topics included: An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide The importance of monitoring side effects and strategies to mitigate them Insights from recent studies, highlighting the impact of these medications on patient quality of life A discussion on the role of shared decision-making in treatment options for prostate cancer patients   Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!   #ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

    Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

  2. 5 days ago ·  Video

    Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan

    Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression. In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes. The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies. Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support. Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us. Episode Highlights: Overview of MDS and its treatment landscape Case discussions on treatment decisions for anemia and disease progression Insights on the use of luspatercept and hypomethylating agents Management of side effects and the importance of patient education Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/  Thanks for tuning in! We are the Oncology Brothers. #MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers

    Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan

  3. 10 Aug ·  Video

    Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS). We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions.   Key topics included: Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept The significance of ring sideroblasts and del(5q) in treatment selection The management of anemia, thrombocytopenia, and neutropenia in MDS patients The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology! #MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers

    Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc

  4. 6 Aug ·  Video

    Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Klein

    Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer. In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Klein, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the emerging role of novel therapies like RAS inhibitors. Key topics include: Overview of current treatment paradigms for metastatic pancreatic cancer Discussion of side effects and patient management strategies The importance of communication and collaboration within the oncology team Insights into the future of pancreatic cancer treatment and the potential of new therapies Whether you're a healthcare professional, a patient, or simply interested in oncology, this episode offers valuable perspectives on delivering compassionate and effective cancer care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #PancreaticCancer, #PartnersInPractice, #RASinhibitors, #OncologyBrothers

    Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Klein

  5. 3 Aug ·  Video

    Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)

    In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

    Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)

  6. 30 Jul ·  Video

    Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

    In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.   Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection based on patient age, prior therapy, drug exposure, and disease biology The importance of shared decision-making and incorporating patient preferences into treatment planning Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

    Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

  7. 28 Jul ·  Video

    ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients.   Key topics include: Overview of the ENDURANCE trial and its implications for clinical practice The significance of limiting lenalidomide maintenance therapy to two years The role of minimal residual disease (MRD) testing in treatment decisions Insights on high-risk cytogenetics and future directions for therapy   This episode is a must-listen for community oncologists and anyone interested in the evolving landscape of cancer treatment. Tune in to learn how these findings can impact patient care and improve outcomes!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and challenging cases in oncology. #MultipleMyeloma, #ENDURANCE, #Lenalidomide, #MRD, #OncologyBrothers

    ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma

  8. 23 Jul ·  Video

    Managing Toxicities of CAR-T in Multiple Myeloma (MM) – Drs. Caitlin Costello & Joshua Richter

    In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.   We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), as well as the role of prophylactic treatments and the importance of bridging therapy.   This episode emphasized the critical collaboration between community oncologists and academic institutions to ensure patients receive the best care possible. Tune in to understand how to navigate the complexities of CAR-T therapies and empower your patients with the knowledge they need.   Key Topics: Overview of CAR-T therapies for multiple myeloma Common side effects: CRS and ICANS Management strategies for acute and chronic toxicities The role of prophylactic treatments Importance of communication between community and academic oncologists   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #CARTtherapy, #MultipleMyeloma, #CRS, #ICANS, #OncologyBrothers

    Managing Toxicities of CAR-T in Multiple Myeloma (MM) – Drs. Caitlin Costello & Joshua Richter
See All (100)

Ratings & Reviews

4
out of 5
2 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like